Molecular Templates (MTEM) 10-Q2016 Q1 Quarterly report

Filed: 5 May 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: aberrant, accrued, alleviated, alter, altogether, analyze, appeal, ASCO, Asian, bid, biomarker, biopharmaceutical, borne, calendar, CI, clarifying, closure, concomitant, contingent, covalent, cure, death, dedicate, deficiency, delist, delisted, delisting, depressed, divest, float, footnote, free, Gastrointestinal, GI, grow, hazard, history, HR, IDSMB, illustrate, implementation, implemented, implementing, implicated, Japan, Japanese, July, Korean, lesser, letter, liquidity, meaningful, meaningfully, median, middle, mitigating, monotherapy, mutually, noncurrent, nonrefundable, notification, notified, notify, notwithstanding, novelty, original, originally, path, payout, percent, PFS, PMDA, presence, purpose, ratio, reanalyzed, regain, release, reverse, reversed, shut, split, spread, staffing, statutory, subgroup, Symposium, Tagrosso, talented, therewith, topline, turnover, type, vice, wind, workforce

Removed: accurate, achievability, activated, adjustment, administering, amendment, applicability, approving, arbitration, assessed, assigned, ASU, authority, base, bortezomib, breach, broad, broaden, Carlo, carry, chose, compare, convertible, deducting, dexamethasone, difficulty, direct, discovering, earn, ending, enhancement, epidermal, equal, exchangeable, excluding, exercisable, factor, final, foregoing, Genentech, geographic, half, Hedging, Hematology, ifosfamide, incorrect, initiate, initiated, initiation, international, invalidate, invite, jeopardize, June, low, Mark, Matteucci, MLV, Monte, myeloma, noted, open, optimize, partially, payable, PET, point, preliminary, preparing, proceed, properly, propose, proteasome, receptor, record, relationship, remeasured, remedy, restate, retrospective, selected, selectivity, simulation, steering, task, thereof, tolerability, tolerated, ultimate, unchanged, uncured, underwriting, University, updated, Velcade, virtue, working

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

MTEM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

THRESHOLD PHARMACEUTICALS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Threshold Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joel A. Fernandes, Vice President, Finance and Controller of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 5, 2016

/s/ Joel A. Fernandes

Joel A. Fernandes

Vice President, Finance and Controller

(Principal Financial Officer)